Overview

A Study of LY2140023 in Hepatically-Impaired Participants

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will explore how liver impairment affects blood levels of LY2140023 (a prodrug) and its active metabolite (LY404039).
Phase:
Phase 1
Details
Lead Sponsor:
Denovo Biopharma LLC
Eli Lilly and Company